Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Benefit of allogeneic transplantation in patients age = 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.

Michelis FV, Messner HA, Atenafu EG, Kim DD, Kuruvilla J, Lipton JH, Uhm J, Loach D, Gupta V. Benefit of allogeneic transplantation in patients age = 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant. Biol Blood Marrow Transplant. 2014 Apr; 20(4):474-9.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.